City Therapeutics has announced its launch accompanied by a $135m Series A financing to lead advancements in RNAi-based ...

Ipsen has received the UK MHRA's approval for its Elafibranor (Iqirvo) for the treatment of primary biliary cholangitis (PBC) ...

The manufacturing shift to meet growing cell and gene therapy demand, applying lessons from the Covid-19 pandemic to address ...

Less frequent dosing could provide Eli Lilly’s Ebglyss room to rival Sanofi and Regeneron’s blockbuster Dupixent.

The companies will collaborate to hold a global Phase I combination trial of YL201 and Amgen’s Imdelltra for small cell lung ...

Bayer has entered a collaboration with MOMA Therapeutics in which the two companies will advance a small molecule oncology ...

The MHRA’s 2024/25 business plan focuses on improving service delivery for its customers, enabling access to new technologies ...

The Phase III trials will evaluate survodutide in metabolic dysfunction-associated steatohepatitis (MASH), fibrosis and ...

ViiV Healthcare has announced plans to triple annual supply of long-acting cabotegravir for HIV PrEP to at least two million ...

Innovent Biologics and ASK Pharm have signed a strategic partnership for the commercialisation of limertinib for the ...

OnKure has announced the successful completion of its merger with Reneo Pharmaceuticals, forming the combined entity ...

NP001 is designed to tackle the neurodegenerative disease through an immunologic mechanism as opposed to a neurologic one.